358 related articles for article (PubMed ID: 29027522)
1. [Morphochemical changes in the substantia nigra cellular structures in Parkinson's disease].
Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB; Kutukova KA
Arkh Patol; 2017; 79(5):3-9. PubMed ID: 29027522
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
4. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
5. [Lewy bodies in Parkinson's disease: histological, immunohistochemical, and interferometric examinations].
Voronkov DN; Salkov VN; Anufriev PL; Khudoerkov RM
Arkh Patol; 2018; 80(4):9-13. PubMed ID: 30059066
[TBL] [Abstract][Full Text] [Related]
6. Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease.
Gertz HJ; Siegers A; Kuchinke J
Brain Res; 1994 Feb; 637(1-2):339-41. PubMed ID: 8180816
[TBL] [Abstract][Full Text] [Related]
7. [Morphochemical study of alpha-synuclein, iron and iron-containing proteins in the substantia nigra of the brain in Parkinson's disease].
Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB
Arkh Patol; 2022; 84(2):13-19. PubMed ID: 35417944
[TBL] [Abstract][Full Text] [Related]
8. [Neurochemical and morphological changes of microstructures of the compact part of the substantia nigra of human brain in aging and Parkinson's disease (literature review).].
Salkov VN; Khudoerkov RM
Adv Gerontol; 2018; 31(5):662-667. PubMed ID: 30638319
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons.
Tompkins MM; Basgall EJ; Zamrini E; Hill WD
Am J Pathol; 1997 Jan; 150(1):119-31. PubMed ID: 9006329
[TBL] [Abstract][Full Text] [Related]
12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
13. Colloid (hyaline) inclusion bodies in the central nervous system: their presence in the substantia nigra is diagnostic of Parkinson's disease.
Pappolla MA; Shank DL; Alzofon J; Dudley AW
Hum Pathol; 1988 Jan; 19(1):27-31. PubMed ID: 2447008
[TBL] [Abstract][Full Text] [Related]
14. [Morphological parameters of the heterogeneity of the substantia nigra in elderly men and women].
Salkov VN; Khudoerkov RM; Voronkov DN; Noss NS
Arkh Patol; 2015; 77(4):51-54. PubMed ID: 26485780
[TBL] [Abstract][Full Text] [Related]
15. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease.
Iannaccone S; Cerami C; Alessio M; Garibotto V; Panzacchi A; Olivieri S; Gelsomino G; Moresco RM; Perani D
Parkinsonism Relat Disord; 2013 Jan; 19(1):47-52. PubMed ID: 22841687
[TBL] [Abstract][Full Text] [Related]
16. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
[TBL] [Abstract][Full Text] [Related]
19. [Incidental occurrence of Lewy bodies in the brains of elderly patients--the relevance to aging and Parkinson's disease].
Wakabayashi K; Takahashi H; Oyanagi K; Ikuta F
No To Shinkei; 1993 Nov; 45(11):1033-8. PubMed ID: 8135950
[TBL] [Abstract][Full Text] [Related]
20. [Morphometric assessment of lesions in the dopaminergic nigrostriatal system in Parkinson disease].
Bertrand E; Lechowicz W; Szpak GM; Dymecki J
Neurol Neurochir Pol; 1996; 30(5):751-62. PubMed ID: 9148173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
